In 2016, the Beckley/Imperial Research Programme released a study that revealed the staggering potential of psilocybin to alleviate treatment-resistant depression, with 67 percent being depression free after one week and 42 percent remaining in remission three months later. Collaborating with highly prestigious universities, the Beckley Foundation has also conducted research indicating the efficacy of psilocybin as an aid to smoking cessation. Using the latest brain-imaging techniques, we have shed some light on how psilocybin may produce its therapeutic effects, by generating a more ‘entropic’ pattern of brain connectivity, with increased communication throughout the brain leading to more flexible modes of cognition.